Future of GLP-1 Agonists ******** from Ian Blumer, MD, FRCPC, Charles H Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada, Author of Diabetes for Canadians for Dummies , and Celiac Disease for Dummies Compiled by Farhan Guard and Eric Nielsen, Ambulatory Care Pharmacy rotation students
2025 Mar 20;26(6):2797
Moreover, patients with ESKD show an expansion of proteolytic bacteria involved in uremic toxins metabolism but a reduced relative abundance of carbohydrate-fermenting bacteria such as Lactobacillacea e and Prevotellaceae families (Wong et al., 2014)
wounds treated topically with the application of normal saline (NS), blank micelles in hydrogel (MeH), curcumin encapsulated in polymeric micelles (CureM) or hydrogel loaded with CureM (CureMeH)
However, there are several key differences between the two